Microarray analysis of differentially expressed microRNAs in myelodysplastic syndromes

Abstract

Background: Our study aimed to analyze differential microRNA expression between myelodysplastic syndromes (MDS) and normal bone marrow, and to identify novel microRNAs relevant to MDS pathogenesis. Methods: MiRNA microarray analysis was used to profile microRNA expression levels in MDS and normal bone marrow. Quantitative real-time polymerase chain reaction was employed to verify differentially expressed microRNAs. Results: MiRNA microarray analysis showed 96 significantly upregulated (eg, miR-146a-5p, miR-151a-3p, miR-125b-5p) and 198 significantly downregulated (eg, miR-181a-2-3p, miR-124-3p, miR-550a-3p) microRNAs in MDS compared with normal bone marrow. The quantitative real-time polymerase chain reaction confirmed the microarray analysis: expression of six microRNAs (miR-155-5p, miR-146a-5p, miR-151a-3p, miR-221-3p, miR-125b-5p, and miR-10a-5p) was significantly higher in MDS, while 3 microRNAs (miR-181a-2-3p, miR-124-3p, and miR-550a-3p) were significantly downregulated in MDS. Bioinformatics analysis demonstrated that differentially expressed microRNAs might participate in MDS pathogenesis by regulating hematopoiesis, leukocyte migration, leukocyte apoptotic process, and hematopoietic cell lineage. Conclusions: Our study indicates that differentially expressed microRNAs might play a key role in MDS pathogenesis by regulating potential relevant functional and signaling pathways. Targeting these microRNAs may provide new treatment modalities for MDS.

miR-155-5p PROMOTES CD34+ APOPTOSIS AND INHIBITS BONE MARROW HEMATOPOIESIS IN MYELODYSPLASTIC SYNDROMES BY RAC1/CREB/MIR-15B AXIS

“… 21 In the course of MDS, miR-155-5p has been validated to present an up-trend expression level and is associated with high-risk MDS. 5 Furthermore, the increase of miR-155-5p has been also checked in the bone marrow of acquired aplastic anemia patients. 22 miR-155-5p concentration is elevated in the serum of AML patients and is feasible to distinguish AML patients.…”

“…It is underlined that miRNAs with differential expression may represent pathogenic implications of MDS in part by regulating hematopoiesis, and miR-155-5p is an upregulated miRNA in MDS. 5 More importantly, miR-155 transcript maintains a high level in CD34 + MDS cells 6 and miR-155 can decrease RAC1 protein to regulate MDS neutrophils migration. 7 RAC1, a member of the Rho GTPases family, functions in various hematopoietic cell lineages 8 and RAC1 activation promotes human hematopoietic stem and progenitor cell maintenance.…”

Single-Nucleotide Polymorphisms in the 3' Untranslated Region of CORIN Associated With Cardiovascular Diseases in a Chinese Han Population: A Case–Control Study

“…Target loss with rs4695253 was predicted for six miRNAs: MiR-1264 was upregulated in the circulation 3 h after ischemia ( 51 ) and critical limb ischemia in T2DM ( 52 ), and downregulated in neuroglioma ( 53 ). MiR-550a-3p was downregulated in myelodysplastic syndromes ( 54 ). MiR-550a-3p also plays its tumor-suppressor role by directly repressing ERK1 and ERK2 protein expression, thereby suppressing the oncogenic ERK/RSK cascade to reduce breast cancer cell viability, survival, migration, invasion, tumorigenesis, and metastasis ( 55 ).…”

Potential Roles of miRNA-1245a Regulatory Networks in Sarcopenia

“…miR-550a-3p can negatively regulate the expression of ERK1 and ERK2. 13 Upregulation of miR-550a-3p in sarcopenia may lead to the downregulation of the ERK1/2 signaling pathway. A previous study showed that Hachimijiogan promoted the proliferation of C2C12 skeletal muscle cells through the ERK1/2 signaling pathway without activation of the Akt signaling pathway.…”